Physician Education: Bridging Clinical Research and Patient Care

Faculty Profile

Chief, Division of Infectious Diseases
Denver Health Medical Center
Denver, Colorado

Topics of Professional Interest:
  • Hepatitis C virus (HCV) and HIV coinfection
  • In vitro assessment of novel antiviral drugs
  • HCV resistance
  • Viral fitness
  • Early clinical trials of new antiviral drugs (phase I and II)
Current Professional Summary:

Dr Wyles is a Chief, Division of Infectious Diseases at Denver Health Medical Center. His research interests include the in vitro evaluation of new anti-HCV compounds and  clinical trials of anti-HCV compounds in HCV and HCV/HIV co-infected subjects. He serves as an attending physician on the infectious diseases and internal medicine services at the University of California San Diego teaching hospitals. He is an Instructor in the School of Medicine Medical Microbiology laboratory course.

Committees and Organizations:
  • Member, Infectious Diseases Society of America
  • Contributor, Expert Perspectives III: Strategies for the Management of HIV/HCV Co-Infection (2002)
  • Advisor/Instructor, Colorado AIDS Education and Training Center: Hepatitis C Virus Center for Excellence (2002-2005)
  • Consultant, Colorado AIDS Education and Training Center: Hepatitis C Virus Center for Excellence (2005-present)
Honors and Awards:
  • Tau Beta Pi, Engineering Honor Society
  • GlaxoSmithKline HIV Fellow
Education:
  • Northwestern University, BS Biomedical Engineering (1993)
  • Northwestern University Feinberg School of Medicine, MD (1998)
  • University of Colorado Health Sciences Center, Residency in Internal Medicine (1998-2001)
  • University of Colorado Health Sciences Center, Fellowship in Infectious Diseases (2001-2004)

Selected Publications:
  1. Wyles DL, Gerber JG. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis. 2005;40:174-181.
  2. Wyles DL, Gerber JG. Abacavir pharmacokinetics in hepatic dysfunction. Clin Infect Dis. 2005;40:909-910.
  3. Wyles DL, Kaihara KA, Vaida F, Schooley RT. Synergy of small molecular inhibitors of hepatitis C virus replication directed at multiple viral targets. J Virol. 2007;81:3005-3008.
  4. Grünberger C, Wyles DL, Kaihara KA, Schooley RT. Three-drug synergistic interactions of small molecular inhibitors of HCV replication. J Infect Dis. 2008;197:42-45.
  5. Wyles DL, Kaihara KA, Korba BE, Schooley RT, Beadle JR, Hostetler KY. The octadecyloxyethyl ester of (S)-9-[3-hydroxy-2-(phosphonomethoxy) propyl]adenine is a potent and selective inhibitor of hepatitis C virus replication in genotype 1A, 1B, and 2A replicons. Antimicrob Agents Chemother 2009; 53(6):2660-2.

    6. Parsons J, Castaldi MP, Dutta S, Dibrov SM, Wyles DL, Hermann T. Conformational inhibition of the hepatitis C virus internal ribosome entry site RNA. Nat Chem Biol 2009; 5(11):823-5.

Presentations

Management of Hepatitis C Virus in the New Era: Small Molecules Bring Big Changes

An Intensive Workshop on Evolving Strategies in Hepatitis C Management

15th Ryan White HIV/AIDS AETC Program Clinical CARE Conference: Moving Forward with CARE: Focusing on Passion, Purpose, and Excellence

Hepatitis C Virus Infection: Looking Beyond the Interferon Alfa Era

An Advanced CME Live Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management

An Advanced CME Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management